180
Omalizumab in children with allergic
asthma
1
Lanier B,
et al
.
J Allergy Clin Immunol
2009;124:1210–6;
2
Kulus M,
et al
.
Curr Med Res Opin
2010;26:1285–93;
3
Milgrom H,
et al
.
Pediatrics
2001;108:e36;
4
Busse W,
et al
.
N E
n
gl J Med
2011;364:1005–15.
IA05
1
Moderate‐to‐severe
Severe
IA05-EU
2
Moderate‐to‐severe
(well controlled)
N=334
Primary endpoint:
steroid sparing
28 Weeks
010
3
Persistent asthma
(any severity)
N=419
Primary endpoint:
symptom‐free days
60 Weeks
ICATA
4
N=246
Primary endpoint:
exacerbations
52 Weeks
N=628
Primary endpoint:
exacerbations
52 Weeks
ICON and omalizumab: rationale
•
Age
–
Not specified (to reduce complication, age limits indicated by each
product’s specifications)
•
Phenotype description
–
Not specified (suggested as a next step in guideline development,
should be done for all medications/management strategies)
•
Include in the algorithm
–
Clearly an important choice
•
Place in therapy (in relation to oral steroids)
–
Oral steroids should be a last resort in asthma
•
Omalizumab is a good choice for specified patients
Papadopoulos NG, et al. Allergy 2012;67:976−97.
Simposium
